Exercise Medicine to Enhance Cancer Treatment: The ERADICATE Study
Overview
The ERADICATE study explores how exercise can improve the effectiveness of radiation therapy for prostate cancer. Tumors often lack sufficient blood flow, leading to treatment resistance. This study aims to see if exercise can help by improving blood flow and reducing tumor hypoxia.
Study Design
This is a phase II randomized controlled trial involving 50 prostate cancer patients. They will be divided into two groups:
- Exercise Group: Patients will receive external beam radiation therapy (EBRT) along with supervised exercise sessions.
- Control Group: Patients will receive only EBRT.
The exercise program includes moderate to vigorous aerobic and resistance training, conducted two to three times a week for 60 minutes each session. The study will measure treatment response and other health outcomes at various stages: before treatment, immediately after, and during follow-ups at 3 months, 2 years, and 5 years.
Expected Benefits
The ERADICATE study aims to:
- Improve the effectiveness of radiation therapy.
- Reduce side effects of treatment.
- Enhance the quality of life for prostate cancer patients.
Clinical Relevance
This research could lead to new ways to make radiation therapy more effective for prostate cancer patients. By integrating exercise into treatment, we may achieve better health outcomes.
Trial Registration
The study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12624000786594).
Supporting Healthcare Innovation
Clinical trials are essential for developing effective treatments. Our AI-driven platform, DocSym, helps clinicians access vital information easily, improving patient care. With mobile apps for scheduling and telemedicine, we streamline operations and enhance patient outcomes. Learn more at aidevmd.com.
